Table 2 Summary of quality assessment
From: Childhood modifiable risk factors and later life chronic kidney disease: a systematic review
| Â | Â | Â | Â | Â | Selection | Comparability | Outcome | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ID | Author | Year | Total scores | Grade a | Represen-tativeness. of the exposed cohort | Represen-tativeness. of the non-exposed cohort | Ascertainment of the exposure | Outcome of interest was not present at start of study | Controls for age and sex | Considers other relevant covariates | Outcome assessment | Adequacy of follow-up length b | Adequacy of follow-up of cohorts |
1 | Hoq et al. [18] | 2002 | 7 | High | * | * | * | 0 | * | * | * | * | 0 |
2 | Zhao et al. [19] | 2008 | 7 | High | * | * | * | 0 | * | * | * | * | 0 |
3 | Yan et al. [20] | 2018 | 7 | High | * | * | * | 0 | * | * | * | * | 0 |
4 | Yan et al. [21] | 2018 | 7.5 | High | * | * | * | 0 | * | * | * | * | 0.5* |
5 | Zheng et al. [22] | 2018 | 8.5 | High | * | * | * | * | * | * | * | * | 0.5* |
6 | Liao et al. [35] | 2020 | 8.5 | High | * | * | * | * | * | * | * | * | 0.5* |
7 | Liao et al. [24] | 2021 | 8.5 | High | * | * | * | * | * | * | * | * | 0.5* |
8 | Wang et al. [25] | 2022 | 8.5 | High | * | * | * | * | * | * | * | * | 0.5* |
9 | Kim et al. [30] | 2010 | 7 | High | * | * | * | 0 | * | * | * | * | 0 |
10 | Silverwood et al. [26] | 2013 | 8 | High | * | * | * | 0 | * | * | * | * | * |
11 | Yan et al. [27] | 2021 | 7.5 | High | * | * | * | 0 | * | * | * | * | 0.5* |
12 | Liu et al. [28] | 2021 | 7.5 | High | * | * | * | 0 | * | * | * | * | 0.5* |
13 | Wang et al. [29] | 2022 | 8.5 | High | * | * | * | * | * | * | * | * | 0.5* |
14 | Canney et al. [31] | 2018 | 6.5 | Fair | * | * | 0 | 0 | * | * | * | * | 0.5* |
15 | Lv et al. [32] | 2020 | 6 | Fair | * | * | 0 | 0 | * | * | * | * | 0 |
16 | Liu et al. [33] | 2022 | 7.5 | High | * | * | * | 0 | * | * | * | * | 0.5* |
17 | Liu et al. [34] | 2022 | 7.5 | High | * | * | * | 0 | * | * | * | * | 0.5* |